Cognitive reserve (CR) and brain reserve (BR) could offer protective effects on cognition in the early stage of Alzheimer’s disease (AD). However, the effects of CR or BR on cognition in individuals with subjective cognitive decline (SCD) are not clear.
Objective:
To explore the effects of CR and BR on cognition in subjects with SCD.
Methods:
We included 149 subjects from the Sino Longitudinal Study on Cognitive Decline (SILCODE) study. Education was used as a proxy for CR, and head circumference was used as a proxy for BR. Multiple linear regression models were conducted to examine the effects of CR and BR on cognitive scores. Furthermore, we assessed differences in effects between APOEɛ4 carriers with SCD (n = 35) and APOEɛ4 non-carriers with SCD (n = 114) and linear trends among 4 reserve levels (low BR/CR, high BR/low CR, low BR/high CR, and high BR/high CR).
Results:
Both CR and BR had independent positive effects on multiple cognitive measures in SCD participants, and the effects of CR were greater than those of BR. CR has positive effects on cognitive measures in both APOEɛ4 carriers and non-carriers with SCD. However, the positive effects of BR on cognitive measures were observed in APOEɛ4 non-carriers with SCD but not in APOEɛ4 carriers with SCD. Furthermore, there was a linear trend toward better cognitive performance on all cognitive measures in the BR+/CR+ group, followed by the BR–/CR+, BR+/CR–, and BR–/CR–groups.
Conclusion:
This study suggests that both CR and BR have the potential to delay or slow cognitive decline in individuals with SCD.
GBD 2016 Dementia Collaborators (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18, 88–106.
2.
SabayanB, SorondF (2017) Reducing risk of dementia in older age. JAMA317, 2028.
3.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
4.
ScheltensP, BlennowK, BretelerMM, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–17.
JackCJ, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC and TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
7.
KatzmanR, TerryR, DeTeresaR, BrownT, DaviesP, FuldP, RenbingX, PeckA (1988) Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol23, 138–144.
8.
BennettDA, SchneiderJA, ArvanitakisZ, KellyJF, AggarwalNT, ShahRC, WilsonRS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology66, 1837–1844.
9.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFRJ, VisserPJ, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBNM, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaS, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIHGB, RamiL, Resende De OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJB, van Waalwijk Van DoornLJC, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
SternY (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc8, 448–460.
12.
SternYD (2012) Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol11, 1006–1012.
13.
JackCJ, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol12, 207–216.
14.
SternY, Arenaza-UrquijoEM, Bartrés-FazD, BellevilleS, CantilonM, ChetelatG, EwersM, FranzmeierN, KempermannG, KremenWS, OkonkwoO, ScarmeasN, SoldanA, Udeh-MomohC, ValenzuelaM, VemuriP, VuoksimaaE;Reserve Resilience and Protective Factors PIA Empirical Definitions and Conceptual Frameworks Workgroup, (2018) Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement, doi: 10.1016/j.jalz.2018.07.219. [Epub ahead of print].
15.
PerneczkyR, KempermannG, KorczynAD, MatthewsFE, IkramMA, ScarmeasN, ChetelatG, SternY, EwersM (2019) Translational research on reserve against neurodegenerative disease: Consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer’s Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. BMC Med17, 47.
16.
RoeCM, XiongC, MillerJP, MorrisJC (2007) Education and Alzheimer disease without dementia: Support for the cognitive reserve hypothesis. Neurology68, 223–228.
RobitailleA, van den HoutA, MachadoRJM, BennettDA, ČukićI, DearyIJ, HoferSM, HoogendijkEO, HuismanM, JohanssonB, KovalAV, van der NoordtM, PiccininAM, RijnhartJJM, Singh-ManouxA, SkoogJ, SkoogI, StarrJ, VermuntL, CloustonS, Muniz TerreraG (2018) Transitions across cognitive states and death among older adults in relation to education: A multistate survival model using data from six longitudinal studies. Alzheimers Dement14, 462–472.
19.
XuH, YangR, QiX, DinticaC, SongR, BennettDA, XuW (2019) Association of lifespan cognitive reserve indicator with dementia risk in the presence of brain pathologies. JAMA Neurol76, 1184–1191.
20.
van LoenhoudAC, van der FlierWM, WinkAM, DicksE, GrootC, TwiskJ, BarkhofF, ScheltensP, OssenkoppeleR (2019) Cognitive reserve and clinical progression in Alzheimer disease. Neurology93, e334–e346.
21.
BorensteinGA, MortimerJA, BowenJD, McCormickWC, McCurrySM, SchellenbergGD, LarsonEB (2001) Head circumference and incident Alzheimer’s disease: Modification by apolipoprotein E. Neurology57, 1453–1460.
22.
KimJ, StewartR, ShinI, KimS, YangS, YoonJ (2008) Associations between head circumference, leg length and dementia in a Korean population. Int J Geriatr Psychiatry23, 41–48.
GuoL, AlexopoulosP, WagenpfeilS, KurzA, PerneczkyR (2013) Brain size and the compensation of Alzheimer’s disease symptoms: A longitudinal cohort study. Alzheimers Dement9, 580–586.
25.
GrootC, van LoenhoudAC, BarkhofF, van BerckelBNM, KoeneT, TeunissenCC, ScheltensP, van der FlierWM, OssenkoppeleR (2018) Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology90, e149–e156.
26.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
27.
RabinLA, SmartCM, AmariglioRE (2017) Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol13, 369–396.
28.
KielbS, RogalskiE, WeintraubS, RademakerA (2017) Objective features of subjective cognitive decline in a United States national database. Alzheimers Dement13, 1337–1344.
29.
van HartenAC, MielkeMM, Swenson-DravisDM, HagenCE, EdwardsKK, RobertsRO, GedaYE, KnopmanDS, PetersenRC (2018) Subjective cognitive decline and risk of MCI. Neurology91, e300–e312.
MiebachL, WolfsgruberS, PolcherA, PetersO, MenneF, LutherK, IncesoyE, PrillerJ, SpruthE, AltensteinS, BuergerK, CatakC, JanowitzD, PerneczkyR, UtechtJ, LaskeC, BuchmannM, SchneiderA, FliessbachK, KalbhenP, HenekaMT, BrosseronF, SpottkeA, RoyN, TeipelSJ, KilimannI, WiltfangJ, BartelsC, DüzelE, DobischL, MetzgerC, MeiberthD, RamirezA, JessenF, WagnerM (2019) Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res Ther11, 66.
32.
SunY, WangX, WangY, DongH, LuJ, ScheiningerT, EwersM, JessenF, ZuoX, HanY (2019) Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ɛ4 carriers versus APOE ɛ4 non-carriers. Alzheimers Res Ther11, 50.
33.
LiX, WangX, SuL, HuX, HanY (2019) Sino Longitudinal Study on Cognitive Decline (SILCODE): Protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open9, e028188.
34.
ChenG, YangK, DuW, HuX, HanY (2019) Clinical characteristics in subjective cognitive decline with and without worry: Baseline investigation of the SILCODE Study. J Alzheimers Dis72, 443–454.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
37.
PerneczkyR, WagenpfeilS, LunettaKL, CupplesLA, GreenRC, DecarliC, FarrerLA, KurzA (2010) Head circumference, atrophy, and cognition: Implications for brain reserve in Alzheimer disease. Neurology75, 137–142.
38.
PerneczkyR, AlexopoulosP, WagenpfeilS, BickelH, KurzA (2012) Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study. Eur Psychiatry27, 219–222.
39.
KarlawishJ, JackCR, RoccaWA, SnyderHM, CarrilloMC (2017) Alzheimer’s disease: The next frontier—Special Report 2017. Alzheimers Dement13, 374–380.
40.
WuY, BeiserAS, BretelerMMB, FratiglioniL, HelmerC, HendrieHC, HondaH, IkramMA, LangaKM, LoboA, MatthewsFE, OharaT, PérèsK, QiuC, SeshadriS, SjölundB, SkoogI, BrayneC (2017) The changing prevalence and incidence of dementia over time —current evidence. Nat Rev Neurol13, 327–339.
GoldBT (2015) Lifelong bilingualism and neural reserve against Alzheimer’s disease: A review of findings and potential mechanisms. Behav Brain Res281, 9–15.
44.
MazzeoS, PadiglioniS, BagnoliS, BraccoL, NacmiasB, SorbiS, BessiV (2019) The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: A 7-year follow-up study. J Neurol266, 487–497.
45.
MortimerJA, SnowdonDA, MarkesberyWR (2003) Head circumference, education and risk of dementia: Findings from the Nun Study. J Clin Exp Neuropsychol25, 671–679.
46.
DufouilC, AlperovitchA, TzourioC (2003) Influence of education on the relationship between white matter lesions and cognition. Neurology60, 831–836.
47.
BennettDA, WilsonRS, SchneiderJA, EvansDA, MendesDLC, ArnoldSE, BarnesLL and BieniasJL (2003) Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology60, 1909–1915.
48.
RawlingsAM, SharrettAR, MosleyTH, WongDF, KnopmanDS, GottesmanRF (2019) Cognitive reserve in midlife is not associated with amyloid-β deposition in late-life. J Alzheimers Dis68, 517–521.
49.
LiuCC, LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
50.
SafiehM, KorczynAD, MichaelsonDM (2019) ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med17, 64.
51.
Müller-GerardsD, WeimarC, AbramowskiJ, TebrüggeS, JokischM, DraganoN, ErbelR, JöckelK, MoebusS, WinklerA (2019) Subjective cognitive decline, APOE ɛ4, and incident mild cognitive impairment in men and women. Alzheimers Dement (Amst)11, 221–230.
52.
Moreno-GrauS, Rodríguez-GómezO, SanabriaÁ, Pérez-CordónA, Sánchez-RuizD, AbdelnourC, ValeroS, HernándezI, Rosende-RocaM, MauleónA, VargasL, LafuenteA, GilS, Santos-SantosMÁ, AlegretM, EspinosaA, OrtegaG, GuitartM, GailhajanetA, de RojasI, Sotolongo-GrauÓ, RuizS, AguileraN, PapaseyJ, MartínE, PelejaE; Alzheimer’s Disease Neuroimaging Initiative, LomeñaF, CamposF, VivasA, Gómez-ChiariM, TejeroMÁ, GiménezJ, Serrano-RíosM, OrellanaA, TárragaL, RuizA, BoadaM; FACEHBI study group (2018) Exploring APOE genotype effects on Alzheimer’s disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimers Dement14, 634–643.
53.
DikMG, JonkerC, ComijsHC, BouterLM, TwiskJW, van KampGJ, DeegDJ (2001) Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology57, 2217–2222.
KimKR, LeeKS, KimEA, CheongH, OhBH, HongCH (2008) The effect of the ApoE genotype on the association between head circumference and cognition. Am J Geriatr Psychiatry16, 819–825.
56.
LombardiG, PolitoC, BertiV, BagnoliS, NacmiasB, PupiA, SorbiS (2018) Contribution of bilingualism to cognitive reserve of an Italian literature professor at high risk for Alzheimer’s disease. J Alzheimers Dis66, 1389–1395.
